Northwest Biotherapeutics ROE 2024

Northwest Biotherapeutics Aktienanalyse

Šta radi Northwest Biotherapeutics?

Northwest Biotherapeutics Inc is a biotherapy company specializing in immunotherapy and targeted therapy for the treatment of cancer. The company was founded in 1996 and is based in Bethesda, Maryland, USA. The company started as a startup founded by Dr. Alton Boynton, a former Assistant Professor at Georgetown University School of Medicine and an experienced cancer researcher. Recognizing the potential of immunotherapy for the treatment of cancer, Boynton founded the company with the goal of developing new immunotherapy products. In the early 2000s, the company made significant progress. It received FDA approval for a Phase I clinical trial of its first immunotherapy product, DCVax-L, for the treatment of glioblastoma, a type of brain tumor. The company also expanded its presence in Europe and established a subsidiary in the UK. In 2010, the company conducted a successful Phase II trial of DCVax-L and received Fast Track designation from the US Food and Drug Administration (FDA). In 2012, the company was listed on the NASDAQ Capital Market (NASDAQ: NWBO). The business model of Northwest Biotherapeutics Inc is based on the development and commercialization of immunotherapy products for the treatment of cancer. It focuses on developing personalized immunotherapy tailored to the biological characteristics of individual patients. This approach allows the company to develop targeted products that aim at specific types of cancer. Northwest Biotherapeutics Inc has a partnership with the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig, Germany to support its product development. The partnership enables the use of state-of-the-art technologies for the manufacturing and characterization of cell therapies and allows the company to improve its immunotherapy products. The main product of Northwest Biotherapeutics Inc is DCVax-L, a personalized immunotherapy for the treatment of glioblastoma. DCVax-L is a cell-based therapy that uses the patient's dendritic cells to activate the immune system and fight against cancer. DCVax-L has been studied in Phase I and Phase II clinical trials in both the US and Europe. The company is also developing other immunotherapy products, including DCVax-Direct, a therapy for direct injection of dendritic cells into tumors. The company is also working on the development of DCVax-Prostate, a personalized immunotherapy for the treatment of prostate cancer. In addition to its research and development work, the company collaborates closely with patient organizations, scientists, and physicians to raise awareness of immunotherapy and personalized medicine. It also works with regulatory authorities and healthcare systems to facilitate access to its immunotherapy products. In conclusion, Northwest Biotherapeutics Inc is an innovative biotherapy company specializing in the development of personalized immunotherapy products for the treatment of cancer. With its focus on targeted therapy, the company has the potential to advance the field of immunotherapy and improve the quality of life for cancer patients. Northwest Biotherapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE у детаљу

Razjašnjenje povrata na sopstveni kapital (ROE) kompanije Northwest Biotherapeutics

Povraćaj na sopstveni kapital (ROE) kompanije Northwest Biotherapeutics je osnovni pokazatelj koji ocenjuje profitabilnost kompanije u odnosu na sopstveni kapital. ROE, izračunat deljenjem neto dobiti sa sopstvenim kapitalom akcionara, ilustruje efikasnost kompanije u ostvarivanju profita iz investicija akcionara. Viši ROE označava povećanu efikasnost i profitabilnost.

Poređenje iz godine u godinu

Analiza ROE kompanije Northwest Biotherapeutics iz godine u godinu pomaže u praćenju trendova profitabilnosti i finansijskih performansi. Rastući ROE ukazuje na povećanu profitabilnost i stvaranje vrednosti za akcionare, dok opadajući ROE može ukazivati na probleme u stvaranju dobiti ili upravljanju sopstvenim kapitalom.

Uticaj na investicije

ROE kompanije Northwest Biotherapeutics je ključan za investitore koji ocenjuju profitabilnost, efikasnost i privlačnost kompanije kao investicije. Robusni ROE ukazuje na sposobnost kompanije da pretvori investicije sopstvenog kapitala u profit, čime povećava svoju privlačnost potencijalnim i sadašnjim investitorima.

Interpretacija fluktuacija ROE

Promene u ROE kompanije Northwest Biotherapeutics mogu proizaći iz fluktuacija neto dobiti, sopstvenog kapitala ili oboje. Ove fluktuacije se analiziraju sa ciljem procene efikasnosti menadžmenta, finansijskih strategija, kao i povezanih rizika i mogućnosti, te pomažu investitorima u donošenju obrazloženih odluka.

Često postavljana pitanja o Northwest Biotherapeutics akciji

Koliki je ROE (Return on Equity) kompanije Northwest Biotherapeutics ove godine?

ROE kompanije Northwest Biotherapeutics u ovoj godini iznosi 1,37 undefined.

Kako se ROE (Return on Equity) kompanije Northwest Biotherapeutics razvio u poređenju sa prethodnom godinom?

ROE kompanije Northwest Biotherapeutics se u poređenju sa prošlom godinom promenio za 36,82% porastao.

Kakav uticaj visoki ROE (povraćaj na kapital) ima na investitore Northwest Biotherapeutics?

Visok ROE pokazuje da Northwest Biotherapeutics postiže dobar povraćaj kapitala i da je uspešan u monetizaciji svojih investicija. Ovo je za investitore pozitivan indikator.

Koji uticaj ima nizak ROE (Povraćaj na kapital) na investitore Northwest Biotherapeutics?

Nizak ROE može ukazivati na to da Northwest Biotherapeutics ima poteškoće u uspešnom monetizovanju svojih investicija i može biti negativan signal za investitore.

Kako promena ROE (Return on Equity) od Northwest Biotherapeutics utiče na preduzeće?

Promena ROE (povraćaja na kapital) od Northwest Biotherapeutics može biti indikator finansijske performanse kompanije i pokazati koliko je uspešna u odnosu na druge kompanije u istoj industriji.

Kako se izračunava ROE (Povraćaj na sopstveni kapital) od Northwest Biotherapeutics?

ROE (Return on Equity) se izračunava tako što se dobit preduzeća podeli sa ukupnim kapitalom. Formula glasi: ROE = Dobit / Ukupni kapital.

Koji faktori utiču na ROE (Return on Equity) kompanije Northwest Biotherapeutics?

Neki faktori koji mogu uticati na ROE (Return on Equity) kompanije Northwest Biotherapeutics uključuju, između ostalih, efikasnost u korišćenju sopstvenog kapitala, profitabilnost preduzeća i strukturu finansiranja.

Koje strateške mere može preduzeti da poboljša ROE (povrat na kapital)?

Da bi poboljšao ROE (Return on Equity), može preduzeti različite mere kao što su smanjenje troškova, povećanje prihoda, poboljšanje efikasnosti korišćenja kapitala i promene u strukturi finansiranja. Važno je da kompanija izvrši temeljnu proveru svoje finansijske situacije kako bi odredila najbolje strateške mere za poboljšanje ROE (Return on Equity).

Kolika je dividenda koju isplaćuje Northwest Biotherapeutics?

U poslednjih 12 meseci, Northwest Biotherapeutics je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Northwest Biotherapeutics će verovatno isplatiti dividendu od 0 USD.

Kolika je dividendna prinosa za Northwest Biotherapeutics?

Dividendski prinos od Northwest Biotherapeutics trenutno iznosi .

Kada Northwest Biotherapeutics isplaćuje dividendu?

Northwest Biotherapeutics isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Koliko je sigurna dividenda od Northwest Biotherapeutics?

Northwest Biotherapeutics je isplaćivao dividendu svake godine u poslednjih 0 godina.

Kolika je dividenda kompanije Northwest Biotherapeutics?

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

U kom sektoru se nalazi Northwest Biotherapeutics?

Northwest Biotherapeutics se svrstava u sektor 'Zdravlje'.

Wann musste ich die Aktien von Northwest Biotherapeutics kaufen, um die vorherige Dividende zu erhalten?

Da biste primili poslednju dividendu od Northwest Biotherapeutics od 3. 7. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 3. 7. 2024..

Kada je Northwest Biotherapeutics poslednji put isplatio dividendu?

Isplata poslednje dividende izvršena je 3. 7. 2024..

Kolika je bila dividenda od Northwest Biotherapeutics u godini 2023?

U godini 2023 kompanija Northwest Biotherapeutics je isplatila 0 USD kao dividende.

U kojoj valuti Northwest Biotherapeutics isplaćuje dividendu?

Dividende od Northwest Biotherapeutics se isplaćuju u USD.